ArticleKidney international2022
Lipidomic profiling in the Strong Heart Study identified American Indians at risk of chronic kidney disease.
Article in Kidney international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease.JCI insight · 2023Trial
- A framework of biomarkers for renal aging: a consensus statement by the Aging Biomarker Consortium.Life medicine · 2026Article
- Article
- Trans fatty acids alter renal health in TGFβ3 mice with fibrosis revealed by metabolomics and lipidomics.iScience · 2026Article
- Eigenlipids for exploring lipid biology.Journal of lipid research · 2026Review
- Lipidomic markers of habitual physical activity and risk of type 2 diabetes in American Indians.Scientific reports · 2025Article
- Exploring the common genetic basis of metabolic syndrome-related diseases and chronic kidney disease: insights from extensive genome-wide cross-trait analyses.BioData mining · 2025Article
- Metabolomics profiling in multi-ancestral individuals with type 2 diabetes in Singapore identified metabolites associated with renal function decline.Diabetologia · 2025Article
- Phospholipids and Sphingolipids in Osteoarthritis.Biomolecules · 2025Review
- Sphingolipids and Chronic Kidney Disease.Journal of clinical medicine · 2024Review
- Routine cardiac biomarkers for the prediction of incident major adverse cardiac events in patients with glomerulonephritis: a real-world analysis using a global federated database.BMC nephrology · 2024Article
- Lipidomic studies revealing serological markers associated with the occurrence of retinopathy in type 2 diabetes.Journal of translational medicine · 2024Article
- Longitudinal Lipidomic Signature of Coronary Heart Disease in American Indian People.Journal of the American Heart Association · 2024Article
- Circulating Lipoprotein Sphingolipids in Chronic Kidney Disease with and without Diabetes.Biomedicines · 2024Article
- Longitudinal lipidomic signatures of all-cause and CVD mortality in American Indians: findings from the Strong Heart Study.GeroScience · 2023Article
- Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022.Analytical science advances · 2023Review
- Lipidomics profiling of biological aging in American Indians: the Strong Heart Family Study.GeroScience · 2023Article
- Lipid Parameters and the Development of Chronic Kidney Disease: A Prospective Cohort Study in Middle-Aged and Elderly Chinese Individuals.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 2 countries.
Funding
Abstract
Dyslipidemia associates with and usually precedes the onset of chronic kidney disease (CKD), but a comprehensive assessment of molecular lipid species associated with risk of CKD is lacking. Here, we sought to identify fasting plasma lipids associated with risk of CKD among American Indians in the Strong Heart Family Study, a large-scale community-dwelling of individuals, followed by replication in Mexican Americans from the San Antonio Family Heart Study and Caucasians from the Australian Diabetes, Obesity and Lifestyle Study. We also performed repeated measurement analysis to examine the temporal relationship between the change in the lipidome and change in kidney function between baseline and follow-up of about five years apart. Network analysis was conducted to identify differential lipid classes associated with risk of CKD. In the discovery cohort, we found that higher baseline level of multiple lipid species, including glycerophospholipids, glycerolipids and sphingolipids, was significantly associated with increased risk of CKD, independent of age, sex, body mass index, diabetes and hypertension. Many lipid species were replicated in at least one external cohort at the individual lipid species and/or the class level. Longitudinal change in the plasma lipidome was significantly associated with change in the estimated glomerular filtration rate after adjusting for covariates, baseline lipids and the baseline rate. Network analysis identified distinct lipidomic signatures differentiating high from low-risk groups. Thus, our results demonstrated that disturbed lipid metabolism precedes the onset of CKD. These findings shed light on the mechanisms linking dyslipidemia to CKD and provide potential novel biomarkers for identifying individuals with early impaired kidney function at preclinical stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.